Business Context and Reporting Period
Company: Icecure Medical Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: January 2024 (Report No. 4)
Date Filed: January 30, 2024
This filing reports a significant regulatory development regarding the Company's ProSense® device for early-stage breast cancer. The document incorporates by reference a press release issued on January 30, 2024.
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on a regulatory event.
Material Changes
- FDA Appeal Outcome: The U.S. Food and Drug Administration (FDA) granted Icecure Medical's appeal regarding the De Novo Classification Request for the marketing authorization of ProSense® for early-stage breast cancer.
- Regulatory Status: The FDA has reopened the De Novo Classification Request, allowing the Company to proceed with the review process for this specific indication.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates the first five paragraphs and the "Forward Looking Statements" section of the January 30, 2024 press release into the Company's Registration Statements on Form F-3 and Form S-8.
Risks and Contingencies: While the appeal was successful, the filing does not detail specific risks or contingencies beyond the standard forward-looking statements referenced in the incorporated press release. The outcome of the reopened De Novo request remains subject to FDA review.
Investor Verification Checklist
- Verify the full text of the press release dated January 30, 2024 (Exhibit 99.1) for detailed "Forward Looking Statements" and specific next steps.
- Confirm the current status of the De Novo Classification Request on the FDA website following the reopening.
- Review the Company's most recent Form 20-F or quarterly reports for actual financial performance data, as this 6-K contains no financial figures.